Medicare Advantage Crisis Escalating: Medical cost pressures in the core Medicare Advantage business have reached critical levels, with Q3 2025 restructuring charges of $79M nearly equaling the entire prior 9-month 2024 total ($80M), signaling rapid deterioration requiring emergency intervention including probable workforce reductions and facility consolidations. Strategic Retreat from Healthcare…

Our analysis rates this filing BEARISH. The HIGH concern level (7.8/10) reflects a company in crisis mode within its core business segment. Medicare Advantage - Humana's largest and most critical revenue driver - is experiencing fundamental profitability deterioration requiring emergency…

Concern level: HIGH (7.8/10). Key factors: Core Medicare Advantage business experiencing severe medical cost deterioration requiring emergency restructuring (severity 9/10); Restructuring activity accelerated dramatically - Q3 2025 charges ($79M) nearly equal entire 9-month 2024 period ($80M), indicating rapid business condition deterioration; Forced divestiture of Gentiva Hospice business…

Notable risk changes: Medicare Advantage business experiencing severe medical cost pressures requiring emergency restructuring program with $79M in Q3 2025 charges alone - nearly matching entire prior year restructuring spend. This signals fundamental profitability crisis in core business segment.; Company divested Gentiva Hospice business unit, representing strategic retreat from healthcare services vertical.…

The model predicts HUM will outperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.